0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Bevacizumab and Cancer Treatment-Related Mortality

Zu-Yao Yang, MD; Chen Mao, MD; Jin-Ling Tang, MD, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.757.
Text Size: A A A
Published online

Extract

To the Editor: We found some errors in the results in a recent systematic review and meta-analysis of treatment-related mortality with bevacizumab by Dr Ranpura and colleagues.1

The numbers of fatal adverse events (FAEs) were extracted incorrectly or by using different extraction criteria from some of the included studies. In the study by Hurwitz et al,2 the incidence of FAEs (“adverse event leading to death”) was 10 of 393 in the bevacizumab group and 11 of 397 in the placebo group, as opposed to 1 of 393 and 0 of 397 as reported by Ranpura et al.1 In the study by Escudier et al,3 8 of 337 in the treatment group and 7 of 304 in the control group had a “death not due to disease progression,” in contrast to 3 of 337 and 0 of 304 reported by Ranpura et al.1 In addition, the authors used the incorrect denominator for the incidence of FAEs in the study by Saltz et al4: it should be 694 in the bevacizumab group and 675 in the placebo group, instead of 675 in the treatment group and 694 in the control group, as reported in the review.1

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

June 8, 2011
Cornelis J. A. Punt, MD, PhD; Linda Mol, MSc; Miriam Koopman, MD, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.758.
June 8, 2011
Patricia B. Cerrito, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.759.
June 8, 2011
Shenhong Wu, MD, PhD; Vishal Ranpura, MD; Sanjay Hapani, MD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.760.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();